ZA200500169B - Mycoplasma gallisepticum formulation - Google Patents
Mycoplasma gallisepticum formulation Download PDFInfo
- Publication number
- ZA200500169B ZA200500169B ZA200500169A ZA200500169A ZA200500169B ZA 200500169 B ZA200500169 B ZA 200500169B ZA 200500169 A ZA200500169 A ZA 200500169A ZA 200500169 A ZA200500169 A ZA 200500169A ZA 200500169 B ZA200500169 B ZA 200500169B
- Authority
- ZA
- South Africa
- Prior art keywords
- bird
- vaccine
- formulation
- strain
- mycoplasma gallisepticum
- Prior art date
Links
- 241000204022 Mycoplasma gallisepticum Species 0.000 title claims description 100
- 239000000203 mixture Substances 0.000 title claims description 69
- 238000009472 formulation Methods 0.000 title claims description 68
- 229960005486 vaccine Drugs 0.000 claims description 89
- 230000001681 protective effect Effects 0.000 claims description 70
- 241000287828 Gallus gallus Species 0.000 claims description 47
- 241000271566 Aves Species 0.000 claims description 38
- 238000000034 method Methods 0.000 claims description 35
- 241000272496 Galliformes Species 0.000 claims description 20
- 241000204003 Mycoplasmatales Species 0.000 claims description 20
- 210000002345 respiratory system Anatomy 0.000 claims description 19
- 230000001580 bacterial effect Effects 0.000 claims description 14
- 210000001533 respiratory mucosa Anatomy 0.000 claims description 14
- 239000003937 drug carrier Substances 0.000 claims description 11
- 238000004519 manufacturing process Methods 0.000 claims description 11
- 241000204031 Mycoplasma Species 0.000 claims description 8
- 239000000443 aerosol Substances 0.000 claims description 8
- 239000003889 eye drop Substances 0.000 claims description 8
- 239000003651 drinking water Substances 0.000 claims description 5
- 235000020188 drinking water Nutrition 0.000 claims description 5
- 108090001030 Lipoproteins Proteins 0.000 claims description 4
- 239000002773 nucleotide Substances 0.000 claims 4
- 125000003729 nucleotide group Chemical group 0.000 claims 4
- 229940012356 eye drops Drugs 0.000 claims 2
- 108010037896 heparin-binding hemagglutinin Proteins 0.000 claims 2
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 241000286209 Phasianidae Species 0.000 description 48
- 235000013330 chicken meat Nutrition 0.000 description 42
- 201000010099 disease Diseases 0.000 description 20
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 20
- 208000015181 infectious disease Diseases 0.000 description 19
- 230000003902 lesion Effects 0.000 description 15
- 210000000416 exudates and transudate Anatomy 0.000 description 14
- 239000007921 spray Substances 0.000 description 12
- 239000013642 negative control Substances 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- 210000004712 air sac Anatomy 0.000 description 10
- 238000002255 vaccination Methods 0.000 description 10
- 210000004877 mucosa Anatomy 0.000 description 9
- 229920001817 Agar Polymers 0.000 description 7
- 239000008272 agar Substances 0.000 description 7
- 238000013401 experimental design Methods 0.000 description 7
- 230000036039 immunity Effects 0.000 description 7
- 230000002688 persistence Effects 0.000 description 7
- 235000013601 eggs Nutrition 0.000 description 6
- 244000144992 flock Species 0.000 description 6
- 241001415919 Haemorhous mexicanus Species 0.000 description 5
- 230000004520 agglutination Effects 0.000 description 5
- 239000000427 antigen Substances 0.000 description 5
- 108091007433 antigens Proteins 0.000 description 5
- 102000036639 antigens Human genes 0.000 description 5
- 230000002238 attenuated effect Effects 0.000 description 5
- 229940031551 inactivated vaccine Drugs 0.000 description 5
- 238000002955 isolation Methods 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 230000000405 serological effect Effects 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 238000002965 ELISA Methods 0.000 description 4
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 4
- 229960000723 ampicillin Drugs 0.000 description 4
- 238000004166 bioassay Methods 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000011081 inoculation Methods 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 230000004224 protection Effects 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000006196 drop Substances 0.000 description 3
- 210000002257 embryonic structure Anatomy 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 230000035931 haemagglutination Effects 0.000 description 3
- 230000012447 hatching Effects 0.000 description 3
- 230000005847 immunogenicity Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 244000144977 poultry Species 0.000 description 3
- 235000013594 poultry meat Nutrition 0.000 description 3
- 208000023504 respiratory system disease Diseases 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 201000009890 sinusitis Diseases 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241001430197 Mollicutes Species 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000002860 competitive effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 238000012809 post-inoculation Methods 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 210000003437 trachea Anatomy 0.000 description 2
- 230000001018 virulence Effects 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 1
- 208000014085 Chronic respiratory disease Diseases 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000287227 Fringillidae Species 0.000 description 1
- 108010080141 GapA cytadhesin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 101100215624 Mycoplasma gallisepticum gapA gene Proteins 0.000 description 1
- 241000204034 Mycoplasmataceae Species 0.000 description 1
- 208000010359 Newcastle Disease Diseases 0.000 description 1
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000001856 aerosol method Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 229940031567 attenuated vaccine Drugs 0.000 description 1
- 238000010876 biochemical test Methods 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000002497 edematous effect Effects 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 230000008029 eradication Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 229940124452 immunizing agent Drugs 0.000 description 1
- 230000002134 immunopathologic effect Effects 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000009979 protective mechanism Effects 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 238000009589 serological test Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- HQOJMTATBXYHNR-UHFFFAOYSA-M thallium(I) acetate Chemical compound [Tl+].CC([O-])=O HQOJMTATBXYHNR-UHFFFAOYSA-M 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/0241—Mollicutes, e.g. Mycoplasma, Erysipelothrix
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/544—Mucosal route to the airways
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/35—Mycoplasma
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Communicable Diseases (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/194,180 US7217420B2 (en) | 2002-07-13 | 2002-07-13 | Mycoplasma gallisepticum formulation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200500169B true ZA200500169B (en) | 2006-06-28 |
Family
ID=30114683
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200500169A ZA200500169B (en) | 2002-07-13 | 2005-01-07 | Mycoplasma gallisepticum formulation |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US7217420B2 (ko) |
| EP (1) | EP1531861A4 (ko) |
| JP (1) | JP2005533116A (ko) |
| KR (1) | KR20050074428A (ko) |
| CN (1) | CN1688336A (ko) |
| AU (1) | AU2003267992A1 (ko) |
| BR (1) | BR0312640A (ko) |
| MX (1) | MXPA05000467A (ko) |
| RU (1) | RU2005104100A (ko) |
| WO (1) | WO2004006851A2 (ko) |
| ZA (1) | ZA200500169B (ko) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080026386A1 (en) * | 2006-03-31 | 2008-01-31 | Behrens Timothy W | Irf-5 haplotypes in systemic lupus erythematosus |
| TWI422594B (zh) * | 2007-02-02 | 2014-01-11 | Baylor Res Inst | 經由樹狀細胞去唾液酸糖蛋白受體（ｄｃ-ａｓｇｐｒ）接合抗原呈現細胞之藥劑 |
| TW200918666A (en) * | 2007-09-11 | 2009-05-01 | Wyeth Corp | Attenuated mycoplasma gallisepticum strains |
| US20090068231A1 (en) * | 2007-09-11 | 2009-03-12 | Wyeth | Live attenuated mycoplasma strains |
| US8668912B2 (en) | 2009-01-22 | 2014-03-11 | University Of Georgia Research Foundation, Inc. | Mycoplasma gallisepticum formulation |
| UY32570A (es) * | 2009-04-24 | 2010-11-30 | Boehringer Ingelheim Vetmed | Vacuna viva modificada de mycoplasma bovis mejorada |
| US20140147475A1 (en) | 2012-11-29 | 2014-05-29 | Antonius Arnoldus Christiaan Jacobs | Vaccine to protect a ruminant against pneumonia caused by pasteurella multocida |
| EP2976102B1 (en) * | 2013-03-18 | 2019-12-11 | Intervet International B.V. | Vaccine to protect a ruminant against pneumonia caused by mannheimia haemolytica |
| WO2023196374A1 (en) * | 2022-04-06 | 2023-10-12 | University Of Georgia Research Foundation, Inc. | Live mycoplasma gallisepticum vaccines |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1137306A (en) | 1966-07-11 | 1968-12-18 | Research Corp | Inoculum for poultry |
| JPS52134019A (en) | 1976-04-28 | 1977-11-09 | Biseibutsu Kagaku Kenkiyuushiy | Micoplasma galicepticum infection vaccine |
| US5004607A (en) | 1987-08-25 | 1991-04-02 | University Of Georgia Research Foundation, Inc. | Method of immunizing poultry |
| ES2058237T3 (es) | 1987-09-18 | 1994-11-01 | Akzo Nv | Metodo para la preparacion de una vacuna para combatir la infeccion mycoplasmica en aves de corral. |
| DE68914883T2 (de) | 1988-06-02 | 1994-08-18 | Nippon Zeon Co | Geflügel-Mycoplasma-Antigene und das Gen enthaltende rekombinante Vektoren sowie Diagnostika und Vakzine, die diese verwenden. |
| EP0603406B1 (en) | 1992-05-29 | 2001-09-19 | Nippon Zeon Co., Ltd. | Fowl mycoplasma antigen, gene thereof, recombinant vector containing said gene, and vaccine prepared by utilizing the same |
| DE69435169D1 (de) | 1993-03-31 | 2009-01-02 | Zeon Corp | Polypeptid, dafür kodierende DNA, diese DNA beinhaltender, rekombinanter Vektor, Herstellung eines rekombinanten Virus unter Verwendung dieses Vektors und dessen Anwendung |
| ATE196773T1 (de) | 1993-07-30 | 2000-10-15 | Akzo Nobel Nv | Infektiösen bronchitis virus 4/91 enthaltender geflügel-impfstoff |
| JPH07133295A (ja) | 1993-08-27 | 1995-05-23 | Nippon Zeon Co Ltd | 新規な抗原タンパク質、その遺伝子、及び組み換えバキュロウイルスとその利用 |
| JPH07228542A (ja) | 1994-02-18 | 1995-08-29 | Nippon Seibutsu Kagaku Kenkyusho | 不活化病原体の鶏用気管内投与ワクチン |
| US6270770B1 (en) | 1995-01-06 | 2001-08-07 | Akzo Nobel N.V. | Chicken anaemia agent broiler vaccine |
| ZA978434B (en) | 1996-09-27 | 1998-03-26 | Akzo Nobel Nv | Inactivated vaccines. |
-
2002
- 2002-07-13 US US10/194,180 patent/US7217420B2/en not_active Expired - Fee Related
-
2003
- 2003-07-10 RU RU2005104100/13A patent/RU2005104100A/ru not_active Application Discontinuation
- 2003-07-10 AU AU2003267992A patent/AU2003267992A1/en not_active Abandoned
- 2003-07-10 US US10/520,833 patent/US20060257414A1/en not_active Abandoned
- 2003-07-10 BR BR0312640-4A patent/BR0312640A/pt not_active IP Right Cessation
- 2003-07-10 JP JP2004521808A patent/JP2005533116A/ja not_active Abandoned
- 2003-07-10 MX MXPA05000467A patent/MXPA05000467A/es unknown
- 2003-07-10 WO PCT/US2003/022011 patent/WO2004006851A2/en not_active Application Discontinuation
- 2003-07-10 EP EP03748940A patent/EP1531861A4/en not_active Withdrawn
- 2003-07-10 KR KR1020057000554A patent/KR20050074428A/ko not_active Application Discontinuation
- 2003-07-10 CN CNA038165015A patent/CN1688336A/zh active Pending
-
2005
- 2005-01-07 ZA ZA200500169A patent/ZA200500169B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP1531861A4 (en) | 2006-10-11 |
| AU2003267992A1 (en) | 2004-02-02 |
| US7217420B2 (en) | 2007-05-15 |
| RU2005104100A (ru) | 2005-08-27 |
| KR20050074428A (ko) | 2005-07-18 |
| AU2003267992A8 (en) | 2004-02-02 |
| US20060257414A1 (en) | 2006-11-16 |
| JP2005533116A (ja) | 2005-11-04 |
| EP1531861A2 (en) | 2005-05-25 |
| WO2004006851A2 (en) | 2004-01-22 |
| CN1688336A (zh) | 2005-10-26 |
| MXPA05000467A (es) | 2005-09-30 |
| WO2004006851A3 (en) | 2004-03-18 |
| BR0312640A (pt) | 2005-06-28 |
| US20040009179A1 (en) | 2004-01-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Blackall et al. | Infectious coryza and related bacterial infections | |
| Sandhu | Riemerella anatipestifer infection | |
| ZA200500169B (en) | Mycoplasma gallisepticum formulation | |
| EP2214702B1 (en) | Mycoplasma bovis vaccine and methods of use thereof | |
| CA2699410C (en) | Attenuated mycoplasma gallisepticum strains | |
| JP2013223511A6 (ja) | マイコプラズマ・ボビス ワクチン | |
| JP2011500093A6 (ja) | マイコプラズマ・ボビス ワクチン | |
| WO2012092226A1 (en) | Veterinary vaccine composition against infections caused by salmonella | |
| Boulianne et al. | Pasteurellosis and other respiratory bacterial infections | |
| EP2389433B1 (en) | Mycoplasma gallisepticum formulation | |
| WO2023196374A1 (en) | Live mycoplasma gallisepticum vaccines | |
| AU2008318793B2 (en) | Mycoplasma bovis vaccine | |
| Limsatanun | Development of inactivated mycoplasma gallisepticum vaccine in chickens | |
| US20030149255A1 (en) | Bird diagnostics and treatments | |
| WO1994005783A1 (en) | Novel haemophilus organism and vaccines containing the same | |
| WO2002030321A2 (en) | Bird diagnostics and treatments |